Biotechnology

Lipella Pharmaceuticals

Lipella Pharmaceuticals released FY2025 9 Months Earnings on November 14 EST, with actual revenue of USD 216.12K and EPS of USD -1.2299

Lipella Pharmaceuticals released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -0.28

Lipella Pharmaceuticals released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 86.73K, actual EPS USD -0.3099

Lipella Pharmaceuticals released FY2025 Semi-Annual Earnings on August 14, 2025 (EST) with actual revenue of USD 216.12 K and EPS of USD -0.8299

Lipella Pharmaceuticals Obtains Patent for IC Diagnostic Technology

Lipella and Cook Renew Manufacturing Agreement for LP-310

Lipella Presents Oral Lichen Planus Treatment Data at International Conference

Lipella Pharmaceuticals released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 129.39 K, actual EPS USD -0.64

Lipella's LP-310 Mouthwash Shows Positive Results in Phase 2a Clinical Trials for Oral Lichen Planus

Lipella Pharmaceuticals released FY2024 Q4 earnings on March 28 (EST), actual revenue 173.67 K USD (forecast 0 USD), actual EPS -1.1914 USD (forecast -2.43 USD)

Lipella Pharmaceuticals released FY2024 Annual Earnings on March 28 (EST), actual revenue 536.36 K USD (forecast 363 K USD), actual EPS -4.7899 USD (forecast -7.85 USD)

Lipella Pharmaceuticals Stock Price Rises 68.20%, Experimental Drug LP-310 Shows Good Safety Profile

Lipella Pharmaceuticals released FY2024 9 Months Earnings on November 14 (EST), actual revenue USD 362.69K, actual EPS USD -3.5876

Lipella Pharmaceuticals released FY2024 Q3 earnings on November 14, 2024 (EST), with actual revenue of 80.38 K USD (forecast 0 USD) and actual EPS of -1.2908 USD (forecast -0.96 USD)

Lipeira Pharmaceuticals Receives Nasdaq Delisting Notification

Lipella Pharmaceuticals released FY2024 Q2 earnings on August 13 (EST), actual revenue USD 136.43K (forecast USD 0), actual EPS USD -0.9899 (forecast USD -1.04)

Lipella Pharmaceuticals released FY2024 Semi-Annual earnings on August 13, 2024 (EST) with actual revenue of USD 282.31 K and EPS of USD -2.2875

Libera Pharmaceuticals Initiates Phase 2a Clinical Trial for LP-310 in Treating Oral Lichen Planus

Lipella Pharmaceuticals advances its lead product candidate into Phase 2B

Lipella Pharmaceuticals released FY2024 Q1 earnings on May 9 (EST), actual revenue USD 145.88K, actual EPS USD -1.31

Intelligent Bio Solutions

Anghami

ESH Acquisition

ESH ACQUISITION CORP COM USD0.0001 CL A (S/R 13/06/2028)

Northann

Urgently

Sidus Space

RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT)

Datavault AI

Oriental Rise

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Lipella Pharmaceuticals(LIPO.US)